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Abstract
Background: Here we present the first paired-end sequencing of tumors from genetically engineered mouse
models of cancer to determine how faithfully these models recapitulate the landscape of somatic rearrangements
found in human tumors. These were models of Trp53-mutated breast cancer, Brca1- and Brca2-associated
hereditary breast cancer, and E-cadherin (Cdh1) mutated lobular breast cancer.
Results: We show that although Brca1- and Brca2-deficient mouse mammary tumors have a defect in the
homologous recombination pathway, there is no apparent difference in the type or frequency of somatic
rearrangements found in these cancers when compared to other mouse mammary cancers, and tumors from all
genetic backgrounds showed evidence of microhomology-mediated repair and non-homologous end-joining
processes. Importantly, mouse mammary tumors were found to carry fewer structural rearrangements than human
mammary cancers and expressed in-frame fusion genes. Like the fusion genes found in human mammary tumors,
these were not recurrent. One mouse tumor was found to contain an internal deletion of exons of the Lrp1b gene,
which led to a smaller in-frame transcript. We found internal in-frame deletions in the human ortholog of this
gene in a significant number (4.2%) of human cancer cell lines.
Conclusions: Paired-end sequencing of mouse mammary tumors revealed that they display significant
heterogeneity in their profiles of somatic rearrangement but, importantly, fewer rearrangements than cognate
human mammary tumors, probably because these cancers have been induced by strong driver mutations
engineered into the mouse genome. Both human and mouse mammary cancers carry expressed fusion genes and
conserved homozygous deletions.
Background
Cancers form in humans as a result of the accumulation
of mutations that co-operate together in subversion of
growth control and the cell death signals that would
normally result in apoptosis. Somatic mutations in can-
cer genomes can be classified as those that contribute to
the evolution of the cancer, so-called ‘driver mutations’,
and ‘passenger mutations’ that can be used to reveal the
signature of the underlying mutagenic process, but do
not contribute to tumorigenesis. Generally, passenger
mutations are thought to substantially outnumber driver
mutations, meaning that functional validation is gener-
ally important to distinguish between these types of
mutations. This complexity has led to the development
of genetically engineered mouse models (GEMMs) that
aim to faithfully recreate features of human cancers and
in so doing create a platform for assessing the causality
of candidate cancer genes [1]. Recently, we showed that
there is a significant overlap in the cancer genes and
pathways operative in human and mouse cancers [2].
Despite these similarities, however, there are fundamen-
tal differences in the ways cancers form in the two spe-
cies. Unlike human tumors, cancers that form in mice
are generally chromosomally stable and telomere dys-
function is rare [3]. Mouse cells also appear to be easier
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genic events [4]. Nevertheless, there are many examples
of GEMM tumor models that effectively recapitulate
cardinal features of cognate human cancers [1], suggest-
ing that basic features of many tumor suppressor net-
works, cell cycle checkpoints, and apoptotic pathways
have been conserved through evolution.
Pioneering studies performed over 30 years ago
showed that retroviral insertional mutagenesis could be
used to discover cancer genes in the mouse, and c-Myc,
EviI and Bcl11a/b are just a few genes discovered in this
way [5]. More recently, transposon-mediated mutagen-
esis has been employed for cancer gene discovery in the
mouse [6,7]. Unlike the analysis of human tumors, geno-
mic analysis of mouse cancers is an approach that has
been less widely exploited owing mainly to a lack of
tools. Despite this, screening for DNA aberrations in
GEMM tumors has lead to the discovery of several
important cancer driver genes that have subsequently
been shown to play a role in human cancer [8,9]. Until
now, analysis of structural DNA rearrangements in
mouse tumors has mainly relied on inferred breakpoint
analysis based on copy number changes gleaned from
array-based comparative genomic hybridization (aCGH)
[10]. The major disadvantages of this technique include
the above-base pair resolution, the lack of specific infor-
mation as to how breakpoints relate to one another, and
the techniques’ inability to detect rearrangements that
are copy number neutral. Paired-end massively parallel
sequencing (PE-MPS) can be used to overcome these
i n h e r e n ts h o r t c o m i n g s ,a st h i st e c h n i q u ea l l o w sa l l
sequence rearrangements to be identified at base-pair
resolution, including copy number neutral changes such
as inversions and translocations.
We recently used PE-MPS to find structural rearran-
gements in 24 human breast cancers [11], a malignant
melanoma [12] and a lung cancer [13]. PE-MPS has also
been applied to the analysis of acute myeloid leukemias,
a non-small cell lung cancer, and breast cancers by
others [14-18]. An important limitation of human can-
cer genome sequencing is that the identification of dri-
ver mutations is complicated by the intrinsic
heterogeneity in the genetic background of human
populations, and therefore in the profile of somatic
mutations that may arise. Analysis of cancers arising in
inbred mouse strains, which have a defined genetic
make-up, therefore potentially facilitates the identifica-
tion of driver mutations. Moreover, since mice can be
engineered to carry known cancer causing mutations
that will act as potent promoters of tumor formation, it
m i g h tb ee x p e c t e dt h a tt h er a t i oo fd r i v e rt op a s s e n g e r
mutations will be significantly enriched compared to
human tumors. Finally, experimental tumor models may
permit the identification of genetic aberrations
associated with specific traits such as tumor progression,
metastasis and therapy resistance, which cannot be read-
ily assessed in humans. Together, these advantages make
GEMMs an ideal system to screen for genetic aberra-
tions associated with cancer.
In this study we used PE-MPS to analyze the genomes
of eight mouse mammary tumors derived from four dif-
ferent GEMMs of breast cancer: K14cre;Brca1
flox/flox;
Trp53
flox/flox, K14cre;Brca2
flox/flox;Trp53
flox/flox, K14cre;
Cdh1
flox/flox;Trp53
flox/flox and K14cre;Trp53
flox/flox [19-21]
(Table 1). In these GEMMs, epithelium-specific expres-
sion of Cre recombinase induces mammary tumors dri-
ven by deletion of Trp53 alone, or in combination with
deletion of Brca1, Brca2 or Cdh1 (encoding E-cadherin).
The K14cre;Brca1
flox/flox;Trp53
flox/flox and K14cre;Brca2-
flox/flox;Trp53
flox/flox mice develop mammary tumors with
a defect in homologous recombination (HR) due to
genetic knockout of Brca1 or Brca2, respectively
[22-24]. In contrast, tumors arising in K14cre;Cdh1
flox/
flox;Trp53
flox/flox and K14cre;Trp53
flox/flox mice are HR-
proficient, assuming that they have not gained a func-
tional mutation in a member of the HR repair machin-
ery during their evolution. Our primary aim was to
characterize somatic rearrangements in these different
mouse tumor models to see whether they resemble rear-
rangements found in human breast cancers, while our
secondary aim was to identi f yf e a t u r e so ft h es o m a t i c
rearrangements that may distinguish between HR-profi-
cient and HR-deficient tumors. Discovery of the geno-
mic features that discriminate between these two
functionally different types of tumors may facilitate the
identification of patients with HR-deficient tumors, who
can be effectively treated with platinum drugs [22] or
poly(ADP-ribose) polymerase (PARP) inhibitors [23].
Results
Mouse models used in this study and tumor sequencing
We sought to determine whether the functional abroga-
tion of HR would lead to differences in DNA structural
rearrangements in mouse models of breast cancer. To
test this we used PE-MPS to analyze four HR-deficient
mouse mammary tumors derived from K14cre;Brca1
flox/
flox;Trp53
flox/flox and K14cre;Brca2
flox/flox;Trp53
flox/flox
conditional knock-out mice [19-21], and four tumors
derived from K14cre;Cdh1
flox/flox;Trp53
flox/flox and two
K14cre;Trp53
flox/flox mice that do not carry engineered
mutations in the HR machinery [19-21,24]. All tumors
were genotyped to confirm homozygous deletion of all
flox alleles, except for the K14cre;Trp53
flox/flox tumors,
which showed heterozygous loss of Trp53 as determined
by Southern blot analysis (Additional file 1). We
sequenced the remaining Trp53 allele in these tumors
b u tw e r eu n a b l et oi d e n t i f ya n ys o m a t i cm u t a t i o n s
resulting in a loss of heterozygosity. The features of the
Varela et al. Genome Biology 2010, 11:R100
http://genomebiology.com/2010/11/10/R100
Page 2 of 12samples used in this study are listed in Table 1 and in
the Materials and methods.
We used the Illumina GAII platform at the Sanger
Institute to obtain around 60 million paired-end 37-bp
reads from each sample by sequencing Illumina libraries
prepared using DNA fragmented to around 450 bp
(Additional file 2). Paired-end sequencing resulted in an
average of 7.5 × physical coverage of the mouse genome
of each tumor. Discordantly mapped reads were flagged
as those potentially marking structural rearrangements.
We filtered these reads for the presence of long terminal
repeats and short interspersed repetitive elements
(SINEs) to reduce false positive variant calls. All candi-
date rearrangements spanned by at least two indepen-
dent reads and larger than 10 kbp that passed these
filters were validated using genomic PCR on the tumor
sample and matched normal (spleen) DNA to confirm
that the breakpoint was somatic. An overview of vali-
dated rearrangements is shown in Figure 1 and Addi-
tional file 3. Importantly, we detected the recombination
event associated with Cre-mediated deletion of the
Brca1 alelle (20 kb) in one tumor but we did not detect
the deletions associated with recombination of the Cdh1
(14 kb), Trp53 (8 kb) or Brca2 (7 kb) alleles. As men-
tioned above, our analysis was designed to detect rear-
rangements >10 kb, meaning that we would not expect
to retrieve Cre-mediated Brca2 or p53 rearrangements,
although examination of read data over the Brca2 and
p53 loci provided support for the presence of these dele-
tions. The fact that we were unable to detect Cre-
mediated deletion of Cdh1 in PD3679a or PD3680a or
Brca1 in PD3682a suggests that some rearrangements
are not detectable by our approach, possibly because of
the sequence depth we generated across these tumors,
the repeat structure of the mouse genome at these loci,
or the filtering we performed prior to analysis. In our
previous analysis of human breast cancers we estimated
that we were able to recover around 50% of the struc-
tural rearrangements found in a cancer genome. A simi-
lar figure to that reported by others [11,17].
Somatic rearrangements in mouse models for breast
cancer
In general, tumors with homozygous deletion of Trp53
(PD3681a, PD3682a, PD3683a, PD3684a, PD3679a,
PD3680a) showed a larger number of rearrangements
than the Trp53 heterozygous tumors (PD3685a,
PD3686a) (Figure 1; P < 0.02, two tailed t-test). Two
K14cre;Brca2
flox/flox;Trp53
flox/flox tumors and one K14cre;
Cdh1
flox/flox;Trp53
flox/flox tumor were found to harbor
large amplicons within the same region of chromosome
10. Although these amplicons contained many rearran-
gements, we could not identify any recurrent somatic
event. No specific type of rearrangement was found to
discriminate between the different genotypes of the
tumors sequenced (Figure 1), and as seen in human
breast tumors, mouse mammary tumors showed signifi-
cant heterogeneity in their genomic profiles. Impor-
tantly, none of the mouse mammary tumors showed the
tandem duplication phenotype that we have observed in
human BRCA1-mutated and triple-negative breast
tumors (that is, tumors that do not express ERBB2, and
estrogen and progesterone receptors) [11].
Microhomology and non-template DNA at rearrangement
breakpoints
We used conventional capillary sequencing to determine
the exact DNA sequence at the breakpoints of the rear-
rangements (Figure 2). All tumors showed evidence of
sequence microhomology at the breakpoints, a hallmark
of non-homologous end-joining (NHEJ) or microhomol-
ogy-mediated repair (MHMR) [25]. When specifically
examining the results for the non-amplicon related rear-
rangements, the Brca1-mutated tumors showed a
Table 1 Overview of mouse tumors analyzed
Number of
samples
Genotype Latency
(days)
Homologous
repair
p53 status Reference Identifiers Histology Tumor
(%)
2 K14cre;Trp53
flox/flox 504 Proficient Heterozygous Jonkers et al. 2001
[20]
PD3685a Mesenchymal 75
386 PD3686a Mesenchymal 50
2 K14cre;Cdh1
flox/flox;
Trp53
flox/flox
449 Proficient Null Derksen et al.
2006 [19]
PD3679a mILC
a 85
328 PD3680a mILC
a/
Carcinoma
85
2 K14cre;Brca1
flox/flox;
Trp53
flox/flox
99 Deficient Null Liu et al. 2007 [21] PD3681a Carcinoma 95
247 PD3682a Carcinoma 95
2 K14cre;Brca2
flox/flox;
Trp53
flox/flox
144 Deficient Null Jonkers et al. 2001
[20]
PD3683a Carcinoma 95
227 PD3684a Carcinoma 95
aMouse invasive lobular carcinoma.
Varela et al. Genome Biology 2010, 11:R100
http://genomebiology.com/2010/11/10/R100
Page 3 of 12Figure 1 Overview of somatic rearrangements in mouse mammary tumors. (a) Homologous recombination deficient tumors. (b)
Homologous recombination proficient tumors. Circos plots showing the genome-wide distribution of structural aberrations. An ideogram of the
mouse genome is show in the outer ring. The blue line indicates changes in copy number as determined by read coverage density. Intra-
(green) and inter-chromosomal (purple) rearrangements are shown by lines within the circle. The bar plots show the absolute number of
rearrangements found per type. Dark blue denotes deletions, red denotes tandem duplications, green denotes inversions, light blue denotes
interchromosomal rearrangements, and orange denotes amplifications.
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points, which indicates a potential preference for NHEJ
or MHMR by tumors of this genotype (Figure 2).
Remarkably, the Brca2-mutated tumors with a function-
ally similar defect in HR showed no such inclination
towards microhomology.
Generation of fusion genes and their expression
Validation of the breakpoints led to the prediction of
three in-frame fusion genes, as well as two in-frame
internally rearranged genes. To test whether these pre-
dicted fusions were transcribed, we extracted RNA from
the sequenced tumors and applied RT-PCR using three
distinct primer pairs spanning the predicted fusion
boundaries in the transcript. Two fusion genes
originating from the chromosome 10 amplicon in tumor
PD3680a were found to be expressed (Figure 3). We
confirmed these fusions at the RNA level by capillary
sequencing of RT-PCR products (Figure 3). The fusion
between the genes Rnf217 and Tpd52l1 is the result of a
200-kb tandem duplication (Figure 3a). This fusion tran-
script encodes a protein in which the first two exons of
Tpd52l1, which does not code for any known protein
domains, and all exons of Rnf217, which contains an
abrogated zinc finger domain (IBR-ZNF) with a car-
boxy-terminal transmembrane domain, are joined
together. The largest part of the fusion protein is
derived from Rnf217, the function of which is unknown.
The fusion between Aldh8a1 and 6330407J23Rik is the
result of an 8-Mb deletion. The fusion transcript
Figure 2 Overview of breakpoint sequence homology and non-templated DNA sequence per genotype. The bar plots show the amount
of microhomology and non-templated DNA found binned by sequence length. The plots show aggregate values per genotype, separated into
amplification-associated and non-amplification associated rearrangements.
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dehydrogenase domain of Aldh8a1 fused to a carboxy-
terminal transmembrane domain encoded by the last
four exons of 6330407J23Rik.
Using RT-PCR we screened RNA from an additional
19 K14cre;Brca2
flox/flox;Trp53
flox/flox mouse mammary
tumors, all of which carried the chromosome 10 amplifi-
cation, but we were unable to find any evidence for
expression of either fusion gene in these tumors. We
conclude that, similar to human breast cancers, mouse
mammary tumors contain non-recurrent in-frame fusion
genes.
Internally rearranged genes
Of the two predicted in-frame internally rearranged
genes, one, Lrp1b,w a sf o u n dt ob ee x p r e s s e db yR T -
PCR (Figure 4B). Lrp1b encodes a member of the low
density lipoprotein (LDL) receptor gene family. We con-
firmed the internal deletion of Lrp1b exons 4 to 11 by
capillary sequencing of the RT-PCR product (Figure
4C). The reduced number of reads mapping to the
Lrp1b locus further confirmed the intragenic deletion of
this gene (Figure 4D). The read density at the Lrp1b
locus was similar to the read density at the homozy-
gously deleted Trp53 locus, suggesting homozygous
deletion of Lrp1b.
Internal deletions of human LRP1B
To determine whether the internal deletion of exons in
the Lrp1b gene is relevant to human cancer, we exam-
ined 770 human cancer cell lines for which we had pre-
viously generated high-resolution aCGH (Affymetrix
SNP6) data [26]. We analyzed these cell lines through
the CONAN copy number analysis algorithm [26]. We
then used the PICNIC copy number algorithm [27] to
identify tumors carrying homozygous deletions of exons
of LRP1B. Out of the 770 cell lines, 33 (4.2%) harbored
internal homozygous deletions of LRP1B (Figure 5).
Importantly, deletion of LRP1B did not correlate with
P53 status (P = 0.096). Thirty-two of the LRP1b dele-
tions removed one or more exons and intragenic dele-
tions of LRP1b were predicted to generate in-frame
transcripts in 20 of them. To follow up on this analysis,
we analyzed a collection of 102 sporadic breast cancers
[28] but were unable to identify internal deletions of
LRP1b, suggesting that it is a relatively rare event in
Figure 3 Expressed fusion genes found in tumor PD3680a. (a) Schematic representation of the fusion of genes Tpd52l1 and Rnf217 by
tandem duplication. (b) RT-PCR product of RNA between exon 2 of Tpd52l1 and exon 2 of Rnf217. Sequence trace of the RT-PCR product
confirming the fusion at the RNA level. A schematic representation of the putative fusion gene product. IBR-ZNF, in between ring fingers-zinc
finger domain PF01485; TM, transmembrane domain - predicted by TMHMM. (c) Schematic representation of the fusion of genes Aldh8a1 and
6330407J23Rik by deletion. (d) RT-PCR product of RNA between exon 6 of Aldh8a1 and exon 5 of 6330407J23Rik. Sequence trace of the RT-PCR
product confirming the fusion at the RNA level. A schematic representation of the putative fusion gene product. Retinoic acid DH, aldehyde
dehydrogenase PF00171; TM, transmembrane domain - predicted by TMHMM.
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associated with a subtype of disease not represented by
this dataset.
Discussion
Massively parallel sequencing of tumors from mouse
models of human cancer has several advantages. It per-
mits in-depth analysis of the evolution of cancer genomes
during tumor development, progression and metastasis,
and during therapeutic interventions, including develop-
ment of therapy resistance. Here, we show that PE-MPS
provides an effective means to generate comprehensive
catalogues of somatic structural rearrangements in
tumors from GEMMs of human breast cancer. Com-
pared to our recent study of somatic rearrangements in
human breast cancers, the absolute number of rearrange-
ments we have observed in mouse mammary cancers is
lower [11]. This might be due to the nature of the models
studied where we have engineered into the mouse gen-
ome one or more known tumor-initiating lesions, thus
reducing the requirement for several tumor suppressors
and oncogenes to be mutated. It may also be due to the
fact that these mice develop tumors very quickly, after
about 200 days (K14cre;Brca1
flox/flox;Trp53
flox/flox and
K14cre;Brca2
flox/flox;Trp53
flox/flox and K14cre;Cdh1
flox/flox;
Trp53
flox/flox models) [19-21] or around 400 days
(K14cre;Trp53
flox/flox model) [20] and therefore there is
less opportunity for a substantial passenger mutation
load to accumulate. We previously found that human pri-
mary breast tumors and breast cancer cell lines carry tan-
dem duplications [11]. In contrast, we have not been able
to identify these rearrangements in any of the mouse
tumors we sequenced. The tandem duplication pheno-
type in human tumors might be associated with a specific
breast cancer subtype that is not fully recapitulated by
the mouse models we studied, or these rearrangements
may be associated with the slow kinetics of human breast
cancer development, or possibly of more fundamental
differences between the mouse and human genomes. The
differences in the structure of the mouse and human
mammary cancer genome may also reflect fundamental
differences in the biology of mouse and human cells [4].
Mouse cells, for example, do not undergo telomere ero-
sion and will readily undergo immortilization in vitro,
whereas human cells will enter replicative senescence
under the same conditions. Based on this and other
observations, it has been suggested that fewer mutations
are required to transform or immortalize mouse cells and
Figure 4 The internally rearranged gene Lrp1b/LRP1b. (a) Schematic representation of the Lrp1b internal deletion in PD3682a. (b) RT-PCR
product of RNA between exon 3 and exon 12 of Lrp1b. (c) Sequence trace of the RT-PCR product confirms the fusion between exon 3 and 12.
(d) Read coverage density confirms the deletion of exons 4 to 11.
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tant role in how the genome is rearranged in cancer
makes it plausible to suggest that mouse cancer genomes
may show different rearrangements to their human
counterparts.
T h ep r e s e n c eo fm i c r o h o m o l o g ys e q u e n c e sa tt h e
breakpoints of chromosomal rearrangements is a hall-
m a r ko fN H E Jo rM H M R[ 2 5 ] .W eo n l yf o u n dac l e a r
preference for microhomologous sequences in the non-
amplified rearrangements in the K14cre;Brca1
flox/flox;
Trp53
flox/flox tumors. This could hint towards a depen-
dence of Brca1-deficient tumors on NHEJ. It should be
noted, however, that sample numbers are too low to
draw any statistical conclusions from this observation.
We did not find a clear preference for 0-base microho-
mology in amplified rearrangements as reported for
human breast cancer [11]. Despite the fact that we did
not find compelling evidence for homologous recombi-
nation deficiency in the Brca1-a n dBrca2-deficient
tumors, we have previously shown that tumors from
these models are highly sensitive to the PARP inhibitor
AZD2281 [24]. This may suggest that these tumors
carry a significant load of other rearrangements possibly
driven by defects in other repair mechanisms.
We observed two expressed fusion genes, both origi-
nating from a complex amplification on chromosome 10
in the same K14cre;Brca2
flox/flox;Trp53
flox/flox tumor
(PD3680a). The possible function of these fusion tran-
scripts and their relevance to cancer development are
currently unknown. It is becoming increasingly apparent
that fusion genes are present in a large number of epithe-
lial tumors, but so far few have been shown to be recur-
rent. The amplification on chromosome 10 itself was
found in three samples, yet the minimal amplicon is sev-
eral mega-bases long, containing many genes. Sequencing
a larger number of mouse tumors will be necessary to
define the driver genes in this rearrangement.
Strikingly, the observed rate of homozygous deletions
within LRP1B in human cancer cell lines is equivalent
to or higher than known recessive tumor-suppressor
genes such as PTEN, RB1 and SMAD4 in the same cell
line dataset (Figure 5) [26]. It should be noted, however,
that the LRP1B gene is large (around 2 Mb) so is poten-
tially at higher risk of accumulating homozygous dele-
tions. Moreover, the LRP1B locus is a known fragile site
(FRA2F). This may indicate that deletions at this locus
are sequence driven, rather than associated with tumori-
genesis. In a recent study, however, analysis of human
Figure 5 Human cell lines frequently carry homozygous deletions of the LRP1B gene. (a) Pie chart showing the proportion of the 770 cell
lines containing homozygous deletions in the LRP1B gene. (b) Heatmap showing which exons of the LRP1B gene have been homozygously
deleted. The x-axis shows the exons in transcriptional order. The y-axis shows the different cell lines, clustered using hierarchical Euclidean
clustering on the deletion patterns. The color bar along the y-axis shows whether an in-frame transcript would remain if these exons have been
deleted.
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the least sensitive fragile site in the aphidicolin fragility
assay, and scored highest in a computational measure
for homozygous deletion selection pressure [26].
Furthermore, LRP1B is not only a frequently deleted
gene in tumors but it is also frequently point mutated in
lung cancer, and its promoter is frequently methylated
in several cancer types [29,30]. Analysis of expression
array data available in Oncomine revealed that LRP1b is
expressed in human breast cancer cells, although we
were unable to detect recurrent deletions of LRP1b in a
collection of sporadic primary human breast cancers,
suggesting that deletion of this gene may be a relatively
rare event (Additional file 4), or that it may be asso-
ciated with a specific subtype of disease not represented
by the collection we analyzed [31]. In support of a role
for LRP1b in breast tumorigenesis, it was recently
shown that deletion of LRP1b is associated with the evo-
lution of MCF10A cells, which are an immortal mam-
mary epithelial cell line, into malignant tumors in a
xenograft model of mammary cancer [31]. Thus, LRP1b
may have cell or subtype-specific disease associated
roles in mammary tumorigenesis. We recently developed
two knockout mouse models of Lrp1b in which we dis-
rupted internal exons of the gene revealing a critical
role for this transmembrane receptor in embryonic
development. These mice represent an invaluable tool
for assessing the role of Lrp1b in tumorigenesis [32].
Conclusions
In our study we present the first genome-wide screen
for somatic structural rearrangements in genetically
engineered mouse tumors using PE-MPS. We analyzed
tumors of four genotypes of mouse mammary cancer, of
which two were HR-proficient and two were HR-defi-
cient. We could not find any features of the rearrange-
ments found in these cancers that were specific for
either the HR-proficient or HR-deficient tumor types,
within the small collection of tumors we analyzed. For
n o w ,i ta p p e a r sa st h o u g hN H E Jo rM H M Rp r o c e s s e s
are used as often in HR-proficient tumors as in HR-defi-
cient tumors. As we previously reported for human
mammary tumors, mouse mammary tumors showed evi-
dence of microhomology and non-template DNA repair,
and expressed fusion transcripts, which are a poorly
understood feature of human epithelial tumors.
Materials and methods
Tumor collection
The mouse models of breast cancer used in this study
have been described previously [19-21]. Mutant alleles in
these models were generated in E14 embryonic stem cells
(129P2/Ola) and transmitted onto an FVB/n background.
Tumors were isolated from mice when they became
palpable and were bisected with half the tumor being pro-
cessed for histopathological analysis and the other half
being processed for DNA extraction. Each tumor evolved
in an independent animal. Tumor latency was as follows:
PD3686a (386 days), PD3679a (449 days), PD3685a (509
days), PD3680a (328 days), PD3681a (99 days), PD3682a
(247 days), PD3683a (144 days), PD3684a (227 days).
Tumors were graded for stroma and necrosis. All of the
tumors analyzed in this study were assessed to be com-
posed of, on average, 85% tumor nuclei: PD3686a (50%),
PD3679a (85%), PD3685a (75%), PD3680a (85%), PD3681a
(95%), PD3682a (95%), PD3683a (95%), PD3684a (95%).
Library construction and paired-end sequencing
Genomic libraries from eight mouse mammary cancers
were generated using 5 μgo ft o t a lg e n o m i cD N A .
Briefly, 5 μg of genomic DNA was randomly fragmented
to around 450 bp by focused acoustic shearing (Covaris
Inc. Woburn, Massachusetts, USA). These fragments
were electrophoresed on a 2% agarose gel and the 400-
to 550-bp fraction was excised and extracted using the
Qiagen (Crawley, West Sussex, UK) gel extraction kit
(with gel dissolution in chaotropic buffer at room tem-
perature to ensure recovery of (A+T)-rich sequences).
The size-fractionated DNA was end repaired using T4
DNA polymerase, Klenow polymerase and T4 polynu-
cleotide kinase. The resulting blunt-ended fragments
were A-tailed using a 3′-5′ exonuclease-deficient Klenow
fragment and ligated to Illumina paired-end adaptor oli-
gonucleotides in a ‘TA’ ligation at room temperature for
15 minutes. The ligation mixture was electrophoresed on
a 2% agarose gel and size-selected by removing a 2-mm
horizontal slice of gel at approximately 600 bp using a
sterile scalpel blade. DNA was extracted from the agarose
as above. Ten nanograms of the resulting DNA was PCR-
amplified for 18 cycles using 2 units of Phusion polymer-
ase. PCR cleanup was performed using AMPure beads
(Agencourt BioSciences Corporation Beverly, MA, USA)
following the manufacturer’s protocol. We prepared Gen-
ome Analyzer paired-end flow cells on the supplied Illu-
mina cluster station and generated 37-bp paired-end
sequence reads on the Illumina Genome Analyzer plat-
form following the manufacturer’s protocol. Images from
the Genome Analyzer were processed using the manufac-
turer’s software to generate FASTQ sequence files. These
were aligned to the mouse genome (NCBI build 37)
using the MAQ algorithm v.0.6.8. A detailed breakdown
of the sequencing and mapping of the data for each
tumor is provided in Additional file 2.
Data submission
The sequence data generated as part of this project are
available in the European Nucleotide Archive (ENA).
The project accession is [ENA:ERP000258].
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Reads that failed to align in the expected orientation or
distance apart were further evaluated using the SSAHA
algorithm to remove mapping errors in repetitive
regions of the genome. In addition, during the PCR
enrichment step, multiple PCR products derived from
the same genomic template can occasionally be
sequenced. To remove these, reads where both ends
mapped to identical genomic locations (plus or minus a
single nucleotide) were considered PCR duplicates, and
only the read pair with the highest mapping quality
retained. Further, erroneous mapping of reads originat-
ing from DNA present in sequence gaps in NCBI build
m37 assembly were removed by excluding the highly
repetitive regions within 1 Mb of a centromeric or telo-
meric sequence gap. Additional read pairs, where both
ends mapped to within less than 500 bp of one another,
but in the incorrect orientation, were excluded from
analysis, unless support for a putative rearrangement
was indicated by additional read pairs. The majority of
these singleton read pairs are likely to be artifacts result-
ing from either intramolecular rearrangements gener-
ated during library amplification or mispriming of the
sequencing oligonucleotide within the bridge amplified
cluster. Finally, read pairs where both ends mapped to
within 500 bp of a previously identified germline struc-
tural variant were removed from further analysis, as
these are likely to represent the same germline allele.
Generation of genome-wide copy number plots
Generation of high-resolution copy number plots has
been described previously [11,12,33]. Briefly, the mouse
reference genome was divided into bins of approxi-
mately 15 kb of mappable sequence and high-quality,
correctly mapping read pairs, with a MAQ alternative
mapping quality ≥35, were assigned to their correct bin
and plotted. A binary circular segmentation algorithm
originally developed for genomic hybridization microar-
ray data was applied to these raw plots to identify
change points in copy number by iterative binary seg-
mentation [34].
PCR confirmation of putative rearrangements
The following criteria were used to determine which
incorrectly mapping read pairs were evaluated by confir-
matory PCR: 1, reads mapping ≥10 kb apart spanned by
≥2 read-independent read pairs (where at least one read
pair had an alternative mapping quality ≥35); 2, reads
mapping ≥10 kb apart spanned by 1 read pair (with an
alternative mapping quality ≥35), with both ends map-
ping to within 100 kb of a change point in copy number
identified by the segmentation algorithm; 3, reads map-
ping ≥600 bp apart spanned by ≥2 read-independent read
pairs (where at least one read pair had an alternative
mapping quality ≥35) with both ends mapping to within
100 kb of a change point in copy number identified by
the segmentation algorithm; 4, selected read pairs map-
ping between 600 bp and 10 kb apart spanned by ≥2
independent read pairs (where at least one read pair had
an alternative mapping quality ≥35). Primers were
designed to span the possible breakpoint and to generate
a maximum product size of 1 kb. PCR reactions were
performed on tumor and normal genomic DNA for each
set of primers at least twice, using the following thermo-
cycling parameters: 95°C × 15 minutes (95°C × 30 s, 60°C
× 30 s, 72°C × 30 s) for 30 cycles, 72°C × 10 minutes.
Products giving a band were sequenced by conventional
Sanger capillary methods and compared to the reference
sequence to identify breakpoints. Somatically acquired
rearrangements were defined as those generating a repro-
ducible band in the tumor DNA with no band in the nor-
mal (spleen) DNA following PCR amplification, together
with unambiguously mapping sequence data suggesting a
rearrangement. To support the somatic origin of the
rearrangements identified in this study, we compared our
calls to known structural variants [35]. Importantly,
>95% of our somatic variant calls did not map in the vici-
nity of previously described germline structural variants.
Breakpoint analysis
All breakpoints defined to the base-pair level were used
in the analysis of breakpoint sequence context, exclud-
ing shards and overlapping regions. Analysis was per-
formed on all breakpoints together, and also on subsets
divided into deletions, tandem duplications, amplicons,
other intrachromosomal events, and all interchromoso-
mal events. We extracted 10 bp and 100 bp on either
side of the breakpoint sites for analysis.
RT-PCR analysis of fusion transcripts
RNA was extracted from mouse mammary tumor sam-
ples using Trizol (Invitrogen, Paisley, Scotland, UK) and
reverse transcribed using random hexamers. Three com-
binations of two forward and two reverse PCR primers
were designed to span the fusion breakpoints. Primer
sequences are shown in Additional file 5. We used 2 μlo f
the 1:20 cDNA dilution in the following PCR program:
2.5 min 95°, 35 cycles of (I) 30 s 95° (II) 30 s 58° (III) 50 s
72°, 5 minutes 72°C. If the PCR showed an amplification
product, we employed capillary sequencing with both for-
ward and reverse primers on the PCR product to confirm
the sequence at the exon-exon boundaries and to deter-
mine if the fusion transcript was in-frame.
Sequencing of Trp53 in PD3685a and PD3686a
Primers were design to amplify all exons of Trp53
(ENSMUST00000108658; CCDS36193). The PCR reac-
tions and capillary sequencing were performed in
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ing standard protocols. The resulting traces were aligned
against the mouse reference genome (NCBIM37) using
the BLAST algorithm. We obtained 90.2% sequence cov-
erage of Trp53 in PD3685a and 90.6% sequence cover-
a g eo ft h i sg e n ei nP D 3 6 8 6 a .T r a c e sw e r em a n u a l l y
inspected to identify potential somatic mutations. Pri-
mer sequences are provided in Additional file 6.
Analysis of Affymetrix SNP6 data from human cancer cell
lines
We used the web-based analysis tool CONAN to deter-
mine which cell lines had a homozygous deletion in the
LRP1B gene. We analyzed the PICNIC output for all
cell lines flagged with homozygous deletions at the
LRP1B locus. PICNIC assigns an absolute copy number
score to SNP6 probes [26,27]. To determine the exact
location of the homozygous deletions, we called all
exons within a contiguous region of copy number call =
0 as homozygously deleted.
Additional material
Additional file 1: A Southern blot hybridization showing the status
of Trp53 (p53) in eight tumors sequenced as part of this study. The
PCR primers shown were used to generate a Southern blot probe that
was hybridized with size-fractioned genomic DNA. The ‘wt’ band
represents the wild-type allele. The ‘del’ band represents the recombined
Trp53 allele.
Additional file 2: An overview of the sequencing and sequence
read mapping metrics for the eight mouse mammary cancers
sequenced as part of this study.
Additional file 3: A list of somatic structural rearrangements found
in eight mouse mammary cancers. Each row represents a single
somatically acquired rearrangement. The ‘Sample’ column represents the
mammary cancer that was sequenced as part of this study in which the
rearrangement was found. ‘No. Reads’ denotes the number of mapped
reads spanning the rearrangement. ‘Simplified Nomenclature’ refers to
the type of rearrangement. The ‘Chr1’ column represents the
chromosome on which the rearrangement is resident. For
intrachromosomal rearrangements the ‘Chr2’ column will denote the
same chromosome as shown in the Chr1 column. For interchromosomal
rearrangements Chr2 will carry a different chromosome. Position and
strand represent the location of the rearrangement and the strand to
which the sequence reads have mapped. The ‘Size’ column represents
the distance between the mapped reads for an intrachromosomal
rearrangement while the ‘ReadName’ column reports a single read that
uniquely identifies the rearrangement.
Additional file 4: Copy number analysis of the LRP1b locus in 102
sporadic human breast cancers.
Additional file 5: Primers used for fusion gene validation.
Additional file 6: Primers used to sequence Trp53.
Abbreviations
aCGH: array comparative genomic hybridization; bp: base pair; GEMM:
genetically engineered mouse model; HR: homologous recombination;
MHMR: microhomology-mediated repair; NHEJ: non-homologous end-
joining; PARP: poly(ADP-ribose) polymerase; PE-MPS: paired end massive
parallel sequencing.
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